KMTS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

2 Analyst Rating

Wall Street analysts forecast KMTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMTS is 30.00 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 25.755

Low

28.00

Averages

30.00

High

32.00

Current: 25.755

Low

28.00

Averages

30.00

High

32.00

Piper Sandler

Matt O'Brien

Overweight

maintain

$27 -> $30

2025-12-12

New

Reason

Piper Sandler

Matt O'Brien

Price Target

$27 -> $30

2025-12-12

New

maintain

Overweight

Reason

Piper Sandler analyst Matt O'Brien raised the firm's price target on Kestra Medical to $30 from $27 and keeps an Overweight rating on the shares. The firm notes the company reported strong, full fiscal Q2 results, with almost a 10% beat on the top-line. Gross margin was impressive and adjusted EBITDA loss came in better than expected. Piper views the outlook and a rapidly improving profitability profile as extremely compelling and strongly encourages investors to buy the stock.

Wells Fargo

Overweight

maintain

$27 -> $28

2025-12-12

New

Reason

Wells Fargo

Price Target

$27 -> $28

2025-12-12

New

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Kestra Medical to $28 from $27 and keeps an Overweight rating on the shares. The firm notes the company reported Q2 sales in-line with its pre-announcement and raised FY26 sales guidance above the Q2 beat. Management highlighted an acceleration in WCD market growth, share capture, and improvement in in-network mix and RCM as driving its outlook.

Stifel

Buy

maintain

$28 -> $30

2025-12-12

New

Reason

Stifel

Price Target

$28 -> $30

2025-12-12

New

maintain

Buy

Reason

Stifel raised the firm's price target on Kestra Medical to $30 from $28 and keeps a Buy rating on the shares. Coming in at the high-end of the company's December 1st preannounced sales range, Kestra reported Q2 sales at $22.6M also accelerated gross margins to about 51%, the firm notes. Stifel also points out that encouragingly, management raised full-year 2026 sales guidance to $91M from $88M, previously. As expected, this broadly positive quarterly performance was underpinned by continued ASSURE wearable cardioverter defibrillator share gains and broader market expansion.

Goldman Sachs

Neutral

maintain

$22 -> $25

2025-12-12

New

Reason

Goldman Sachs

Price Target

$22 -> $25

2025-12-12

New

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on Kestra Medical to $25 from $22 and keeps a Neutral rating on the shares. The company's Q2 revenue of $22.6 million came in line with the preliminary guidance update in early December and reflected 53% y/y growth, with the performance in the quarter driven by 54% y/y growth in prescriptions, the analyst tells investors in a research note. Gross margins came in at 50.6% for Q2 and compared to 39.6% in the prior year period and was driven by volume leverage and improving revenue conversion, the firm added.

BTIG

Buy

initiated

$32

2025-11-18

Reason

BTIG

Price Target

$32

2025-11-18

initiated

Buy

Reason

BTIG initiated coverage of Kestra Medical with a Buy rating and $32 price target. The firm says Kestra is "disrupting" the wearable cardioverter defibrillator market with its Assure device. The device offers an improved detection algorithm and more wearable garment, with a digital ecosystem for patients and doctors, the analyst tells investors in a research note. The firm says the company is still in the early stages of its commercial rollout but has already reached 12% share of the existing U.S. market. BTIG expects Kestra's business model to drive improved gross margins and sees continued commercial traction along with "beat-and-raise" quarters.

Valuation Metrics

The current forward P/E ratio for Kestra Medical Technologies Ltd (KMTS.O) is -11.55, compared to its 5-year average forward P/E of -9.54. For a more detailed relative valuation and DCF analysis to assess Kestra Medical Technologies Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.54

Current PE

-11.55

Overvalued PE

-6.36

Undervalued PE

-12.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.83

Current EV/EBITDA

-17.82

Overvalued EV/EBITDA

-9.00

Undervalued EV/EBITDA

-20.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

12.17

Current PS

14.03

Overvalued PS

16.20

Undervalued PS

8.13

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KMTS News & Events

Events Timeline

No data

News

9.5

12-12NASDAQ.COM

Kestra Medical Reports 53% Increase in Q2 Revenue and Raises FY26 Revenue Forecast Once More

9.5

12-03Globenewswire

Kestra Medical to Report Q2 Fiscal 2026 Results on December 11

8.5

12-03NASDAQ.COM

Kestra Increases Price of Primary Public Offering of Common Shares to $23 Each

People Also Watch

Frequently Asked Questions

What is Kestra Medical Technologies Ltd (KMTS) stock price today?

The current price of KMTS is 25.755 USD — it has decreased -1.59 % in the last trading day.

What is Kestra Medical Technologies Ltd (KMTS)'s business?

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.

What is the price predicton of KMTS Stock?

What is Kestra Medical Technologies Ltd (KMTS)'s revenue for the last quarter?

Kestra Medical Technologies Ltd revenue for the last quarter amounts to 22.57M USD, increased 53.40 % YoY.

What is Kestra Medical Technologies Ltd (KMTS)'s earnings per share (EPS) for the last quarter?

Kestra Medical Technologies Ltd. EPS for the last quarter amounts to -0.64 USD, increased 33.33 % YoY.

What changes have occurred in the market's expectations for Kestra Medical Technologies Ltd (KMTS)'s fundamentals?

The market is revising Downward the revenue expectations for Kestra Medical Technologies, Ltd. (KMTS) for FY2026, with the revenue forecasts being adjusted by -0.1% over the past three months. During the same period, the stock price has changed by 13.56%.

How many employees does Kestra Medical Technologies Ltd (KMTS). have?

Kestra Medical Technologies Ltd (KMTS) has 330 emplpoyees as of December 15 2025.

What is Kestra Medical Technologies Ltd (KMTS) market cap?

Today KMTS has the market capitalization of 1.53B USD.